Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Urgency Prediction for Medical Laboratory Tests Through Optimal Sparse Decision Tree: Case Study With Echocardiograms.
JMIR AI
January 2025
Department of Information Systems and Business Analytics, Iowa State University, Ames, IA, United States.
Background: In the contemporary realm of health care, laboratory tests stand as cornerstone components, driving the advancement of precision medicine. These tests offer intricate insights into a variety of medical conditions, thereby facilitating diagnosis, prognosis, and treatments. However, the accessibility of certain tests is hindered by factors such as high costs, a shortage of specialized personnel, or geographic disparities, posing obstacles to achieving equitable health care.
View Article and Find Full Text PDFEco-friendly zinc oxide nanoparticle biosynthesis powered by probiotic bacteria.
Appl Microbiol Biotechnol
January 2025
School of Environmental and Life Sciences, The University of Newcastle, Callaghan, NSW, 2308, Australia.
The rapid advancement of nanotechnology, particularly in the realm of pharmaceutical sciences, has significantly transformed the potential for treating life-threatening diseases. A pivotal aspect of this evolution is the emergence of "green nanotechnology," which emphasizes the environmentally sustainable synthesis of raw materials through biological processes. This review focuses on the biological synthesis and application of zinc oxide (ZnO) nanoparticles (NPs) from probiotic bacteria, particularly those sourced from wastewater.
View Article and Find Full Text PDFProbiotic-based adsorbent mitigates aflatoxin B1 toxicity in Piaractus mesopotamicus: assessing well-being via changes in tissue architecture and digestive enzyme activity.
Vet Res Commun
January 2025
Faculdade de Ciências Agrárias, Universidade Federal da Grande Dourados, Rodovia Dourados - Itahum, km 12, Cidade Universitária, Dourados, MS, Brasil.
Aflatoxin is a mycotoxin produced by fungi of the genus Aspergillus that is present in various foods. Probiotics are well-established products in aquaculture, and due to their effective contribution to the intestine, they can be used as an aflatoxin adsorbent. This study evaluated the effects of aflatoxin B1 (AFB1) on enzymatic activity and intestinal function in Piaractus mesopotamicus (pacu) fingerlings fed diets containing a probiotic-based adsorbent (PBA).
View Article and Find Full Text PDFNano-delivery of a novel inhibitor of ERCC1-XPF for targeted sensitization of colorectal cancer to platinum-based chemotherapeutics.
Drug Deliv Transl Res
January 2025
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB, T6G 2E1, Canada.
In this study, a novel inhibitor of ERCC1/XPF heterodimerization, A4, was used as an inhibitor of repair for DNA damage by platinum-based chemotherapeutics. Nano-formulations of A4 were developed, using self-assembly of the following block copolymers: methoxy-poly(ethylene oxide)-block-poly(α-benzyl carboxylate-ε-caprolactone) (PEO-b-PBCL), methoxy-poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO-b-PCL), or methoxy-poly(ethylene oxide)-block-poly (D, L, lactide) (PEO-b-PDLA 50-50). The nano-formulations were characterized for their average diameter, polydispersity, morphology, A4 encapsulation and in vitro release.
View Article and Find Full Text PDFBaricitinib Provides Significant Improvements in Quality of Life and Functioning in Adults with Moderate-to-Severe Atopic Dermatitis with Baseline Body Surface Area ≤ 40% and Severe Itch.
Dermatol Ther (Heidelb)
January 2025
Department of Dermatology, University of Tsukuba, Tsukuba, Japan.
Introduction: Patients with moderate-to-severe atopic dermatitis (AD), a body surface area (BSA) of ≤ 40%, and an itch numerical rating scale (NRS) score of ≥ 7 ("BARI itch dominant") have been characterized as an important group to consider for the oral janus kinase (JAK) 1/2 inhibitor baricitinib (BARI). Herein we aim to evaluate quality of life (QoL) and functioning outcomes in adult patients with BSA ≤ 40% and itch NRS ≥ 7 at baseline (BL) who received BARI 4 mg in the topical corticosteroid (TCS) combination trial BREEZE-AD7.
Materials: BREEZE-AD7 was a randomized, double-blind, placebo-controlled, parallel-group outpatient study involving adult patients with moderate-to-severe AD who received once-daily placebo or 2-mg or 4-mg BARI in combination with TCS for 16 weeks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!